1.         Fukui K, Masumoto N, Shiroma N, Kanou A, Sasada S, Emi A, Kadoya T, Yokozaki M, Arihiro K, Okada M.　 Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer. Breast Cancer. 2019 Mar 13. doi: 10.1007/s12282-019-00958-3. [Epub ahead of print]

2.         Harada H, Miyamaoto K, Kimura M, Ishigami T, Taniyama K, Okada M. Lung cancer risk stratification using methylation profile in the oral epithelium. Asian Cardiovasc Thorac Ann. 2019 Feb;27(2):87-92.

3.         Okada M, Miyata Y, Takamochi K, Tsutani Y, Oh S, Suzuki K. Prospective feasibility study of sealing pulmonary vessels with energy in lung surgery. J Thorac Cardiovasc Surg. 2019 Jan;157(1):388-395.

4.         Endo S, Ikeda N, Kondo T, Nakajima J, Kondo H, Shimada Y, Sato M, Toyooka S, Okada Y, Sato Y, Yoshino I, Okada M, Okumura M, Chida M, Fukuchi E, Miyata H. Risk assessments for broncho-pleural fistula and respiratory failure after lung cancer surgery by National Clinical Database Japan. Gen Thorac Cardiovasc Surg. 2019 Mar;67(3):297-305.

5.         Ito M, Miyata Y, Kushitani K, Yoshiya T, Kai Y, Tsutani Y, Mimura T, Konishi K, Takeshima Y, Okada M. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma. Thorac Cancer. 2018 Dec;9(12):1594-1602.

6.         Yamaguchi K, Masuda T, Fujitaka K, Miwata K, Sakamoto S, Horimasu Y, Hamai K, Miyamoto S, Nakashima T, Okamoto Y, Iwamoto H, Ishikawa N, Miyata Y, Okada M, Hamada H, Hattori N. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study. In Vivo. 2018 Sep-Oct;32(5):1155-1160.

7.         Masuda M, Endo S, Natsugoe S, Shimizu H, Doki Y, Hirata Y, Kobayashi J, Motomura N, Nakano K, Nishida H, Okada M, Saiki Y, Saito A, Sato Y, Tanemoto K, Toh Y, Tsukihara H, Wakui S, Yokomise H, Yokoi K, Okita Y. Thoracic and cardiovascular surgery in Japan during 2015 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2018 Oct;66(10):581-615.

8.         Tanaka F, Yokomise H, Soejima T, Uramoto H, Yamanaka T, Nakagawa K, Yamamoto N, Nishimura Y, Niwa H, Okada M, Nakagawa T, Yamashita M. Induction Chemo-radiation (50Gy) Followed by Surgery for Stage IIIA-N2 Non-small Cell Lung Cancer. Ann Thorac Surg. 2018 Oct;106(4):1018-1024.

9.         Otsuki T, Nakashima T, Hamada H, Takayama Y, Akita S, Masuda T, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Miyake M, Kohno N, Okada M, Hattori N. Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma. Eur Respir J.2018 May 24;51(5). pii: 1701610. doi: 10.1183/13993003.01610-2017. Print 2018 May.

10.     Amatya VJ, Kushitani K, Kai Y, Suzuki R, Miyata Y, Okada M, Takeshima Y. Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Mod Pathol. Mod Pathol. 2018.

11.     Saji H, Ueno T, Nakamura H, Okumura N, Tsuchida M, Sonobe M, Miyazaki T, Aokage K, Nakao M, Haruki T, Ito H, Kataoka K, Okabe K, Tomizawa K, Yoshimoto K, Horio H, Sugio K, Ode Y, Takao M, Okada M, Chida M; Committee for Scientific Affairs, The Japanese Association for Chest Surgery, Tokyo, Japan. A proposal for a comprehensive risk scoring system for predicting postoperative complications in octogenarian patients with medically operable lung cancer: JACS1303. Eur J Cardiothorac Surg. 2018 Apr 1;53(4):835-841.

12.     Furukawa T, Hamai Y, Hihara J, Emi M, Yamakita I, Ibuki Y, Kurokawa T, Okada M. Impact of Interval Between Neoadjuvant Chemoradiation and Surgery Upon Morbidity and Survival of Patients with Squamous Cell Carcinoma of Thoracic Esophagus. Anticancer Res. 2018 Sep;38(9):5239-5245.

13.     Toyooka S, Okumura N, Nakamura H, Nakata M, Yamashita M, Tada H, Kajiwara S, Watanabe N, Okada M, Sakamoto J, Aoe M, Soh J, Miyoshi S, Hotta K, Matsuo K, Date H. A multi-center randomized controlled study of paclitaxel plus carboplatin versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer. J Thorac Oncol. J Thorac Oncol. 2018 May;13(5):699-706.

14.     Tsubokawa N, Tsutani Y, Miyata Y, Handa Y, Misumi K, Hanaki H, Hida E, Okada M. Segmentectomy Versus Lobectomy for Radiologically Pure Solid Clinical T1a-bN0M0 Lung Cancer. World J Surg. 2018 Aug;42(8):2493-2501.

15.     Ito M, Miyata Y, Okada M. Management pathways for solitary pulmonary nodules. J Thorac Dis. 2018 Apr;10(Suppl 7):S860-S866.

16.     Ishiguro H, Ohno S, Yamamoto Y, Takao S, Sato N, Fujisawa T, Kadoya T, Kuroi K, Bando H, Teramura Y, Iwata H, Tanaka S, Toi M.:Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.Breast Cancer. 2019 Feb 7. doi: 10.1007/s12282-019-00952-9.

17.     Hamai Y, Emi M, Ibuki Y, Murakami Y, Nishibuchi I, Nagata Y, Furukawa T, Kurokawa T, Ohsawa M, Okada M. Early Recurrence and Cancer Death After Trimodal Therapy for Esophageal Squamous Cell Carcinoma. Anticancer Res. 2019 Mar;39(3):1433-1440.

18.     Hamai Y, Hihara J, Emi M, Furukawa T, Murakami Y, Nishibuchi I, Nagata Y, Ibuki Y, Yamakita I, Kurokawa T, Okada M. Preoperative prediction of a pathologic complete response of esophageal squamous cell carcinoma to neoadjuvant chemoradiotherapy. Surgery. 2018 July;164(1):40-48.

19.     Hamai Y, Hihara J, Emi M, Furukawa T, Ibuki Y, Yamakita I, Kurokawa T, Okada M. Treatment Outcomes and Prognostic Factors After Recurrence of Esophageal Squamous Cell carcinoma. World J Surg. 2018 Jul;42(7):2190-2198.

20.     Hamai Y, Hihara J, Emi M, Furukawa T, Murakami Y, Nishibuchi I, Ibuki Y, Yamakita I, Kurokawa T, Nagata Y, Okada M. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery. World J Surg. 2018 May;42(5):1496-1505.

21.     Murakami Y, Hamai Y, Emi M, Hihara J, Imano N, Takeuchi Y, Takahashi I, Nishibuchi I, Kimura T, Okada M, Nagata Y. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma. J Radiat Res. 2018 Sep 1;59(5):616-624.

22.     Masumoto N, Kadoya T, Sasada S, Emi A, Arihiro K, Okada M. Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer. Breast Cancer Res Treat. 2018 Sep;171(2):315-323.

23.     Tsutani Y, Miyata Y, Masuda T, Fujitaka K, Doi M, Awaya Y, Kuyama S, Kitaguchi S, Ueda K, Hattori N, Okada M. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study. BMC Cancer. 2018 Dec 10;18(1):1231. doi: 10.1186/s12885-018-5146-3.

24.     Tsutani Y, Okada M. Bronchoplasties at the Segmental Level. Thorac Surg Clin. 2018 Aug;28(3):299-304.

25.     Sasada S, Masumoto N, Song H, Kajitani K, Emi A, Kadoya T, Arihiro K, Kikkawa T, Okada M. Portable impulse-radar detector for breast cancer: a pilot study. J Med Imaging (Bellingham). 2018 Apr;5(2):025502. doi: 10.1117/1.JMI.5.2.025502. Epub 2018 Jun 13.

26.     Sasada S, Masumoto N, Goda N, Kajitani K, Emi A, Kadoya T, Okada M. Which type of breast cancers is undetectable on ring-type dedicated breast PET? Clin Imaging. 2018 Sep - Oct;51:186-191.

27.     Sasada S, Masumoto N, Goda N, Kajitani K, Emi A, Kadoya T, Okada M. Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: A prospective cohort study. Eur J Surg Oncol. 2018 Apr;44(4):444-448.

28.     Sasada, S., Shien, T., Iwata, H. Current status of postmastectomy radiation therapy in T1-2 breast cancer with limited positive lymph nodes in Japan: Japan Clinical Oncology Group Survey. Breast Cancer 25, 626-627, 2018. (I)

29.     Song, H., Sasada, S., Masumoto, N., Kadoya, T., Shiroma, N., Orita, M., Arihiro, K., Okada, M., Kikkawa, T. Detectability of Breast Tumors in Excised Breast Tissues of Total Mastectomy by IR-UWB-Radar-Based Breast Cancer Imaging. IEEE Trans Biomed Eng. 2018. [Epub ahead of print] (I)

30.     Takahashi, K., Yunokawa, M., Sasada, S., Takehara, Y., Miyasaka, N., Kato, T., Tamura, K. A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma. J Gynecol Oncol 30, e8, 2019. (I)

31.     Yoshiya T, Mimae T, Tsubokawa N, Sasada S, Tsutani Y, Kushitani K, Takeshima Y, Miyata Y, Okada M. The differences in histological changes among pulmonary vessels divided with an energy device. Interact Cardiovasc Thorac Surg. 2018 Sep 1;27(3):372-378.

32.     Kobayashi Y, Kadoya T, Amioka A, Hanaki H, Sasada S, Masumoto N, Yamamoto H, Arihiro K, Kikuchi A, Okada M. Wnt5a-induced cell migration is associated with the aggressiveness of estrogen receptor-positive breast cancer. Oncotarget. 2018 Apr 20;9(30):20979-20992.

33.     Hiraoka E, Mimae T, Ito M, Kadoya T, Miyata Y, Ito A, Okada M. Breast cancer cell motility is promoted by 14-3-3γ. Breast Cancer. 2019 Mar 4. doi: 10.1007/s12282-019-00957-4. [Epub ahead of print]

34.     Kai Y, Tsutani Y, Tsubokawa N, Ito M, Mimura T, Miyata Y, Okada M.　 Prolonged post-recurrence survival following pleurectomy/decortication for malignant pleural mesothelioma.　Oncol Lett. 2019 Mar;17(3):3607-3614.

35.     Kai Y, Tsutani Y, Ito M, Mimura T, Miyata Y, Okada M. Metachronous Lung Cancer After Pleurectomy/Decortication. Ann Thorac Surg. 2019 Jan;107(1):e1-e3.

36.     Kai Y, Amatya VJ, Kushitani K, Kambara T, Suzuki R, Tsutani Y, Miyata Y, Okada M, Takeshima Y. MUC21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma. Histopathology. 2019 Mar;74(4):545-554.

37.     Handa Y, Tsutani Y, Ikeda T, Hanaki H, Miyata Y, Mukaida H, Okada M. Reassessment of Right Middle Lobe Lung Cancer: Comparison of Segments 4 and 5 Tumors. Ann Thorac Surg. 2018 May;105(5):1543-1550.